Vomiting on Ozempic®

How the official documents count vomiting

Vomiting is one of five stomach and bowel rows in Table 1 of the US label, which lists reactions seen in at least 5% of treated adults and more often than on placebo. The data come from two placebo-controlled studies in adults with type 2 diabetes, one with Ozempic® alone and one with basal insulin ^[1]. Europe places vomiting one class below nausea, as common (between 1 in 100 and 1 in 10), and Canada reports it from a larger seven-trial pool with a mixed comparator group ^[2][3].

Dose steps and the 2 mg dose

The US label says most vomiting, nausea and diarrhea reports came during dose escalation. Its dosing section starts treatment at 0.25 mg for four weeks and describes the gradual climb as a way to reduce stomach and bowel reactions; any further step is your prescriber’s call ^[1].

For the 2 mg dose, the US label gives only the stomach and bowel total from its 40-week trial (34% on 2 mg against 30.8% on 1 mg). The European information is more specific: diarrhoea and vomiting were reported by a higher share on 2 mg, while stomach-related stopping was similar on the two doses ^[1][2].

Severe stomach and bowel reactions of any kind were reported in 0.4% on 0.5 mg and 0.8% on 1 mg, with none on placebo. The label says Ozempic® is not recommended in severe gastroparesis, and Europe adds that people with gastroparesis may have more serious or severe stomach effects ^[1][2].

Why fluids sit at the centre of the warnings

Repeated vomiting drains water and salts quickly. Section 5.6 of the US label describes acute kidney injury reported after approval in people using semaglutide, some needing hemodialysis, mostly after stomach reactions had caused dehydration; it asks for kidney function to be monitored in such cases, especially at the start and after dose increases ^[1]. Europe makes the same link and says patients should be told about the dehydration risk and take precautions to avoid fluid depletion ^[2].

MedlinePlus lists the early signs of losing too much fluid as thirst, a dry or sticky mouth, passing little urine, darker yellow urine, headache and muscle cramps. Dizziness, a racing heart, confusion and very dark or no urine point to more severe dehydration ^[7].

Vomiting, an empty stomach and procedures

Because Ozempic® slows stomach emptying, section 5.10 describes rare reports of stomach contents entering the lungs during general anesthesia or deep sedation in people on GLP-1 medicines who had followed fasting instructions. The label says current data cannot tell clinicians how best to reduce that risk ^[1]. Canada and Europe carry similar wording ^[2][3].

A meta-analysis of 23 observational studies with 262,018 people having upper endoscopy found that GLP-1 medicine users had about 4.5 times the odds of food left in the stomach and of the procedure being stopped early, but no difference in aspiration pneumonia. The studies were observational and covered the drug class, not Ozempic® alone ^[4].

What larger semaglutide trials add

In SUSTAIN-6, a two-year trial of 3,297 adults with type 2 diabetes at high cardiovascular risk, fewer serious adverse events occurred on semaglutide than on placebo, but more people stopped treatment because of adverse events, mainly stomach and bowel ones ^[5]. Section 6.1 of the US label adds that in this trial, and in a wider pool of seven trials, common reactions were similar in type and frequency to Table 1 ^[1].

Why it may happen

What the label supports: semaglutide delays stomach emptying a little in the early period after meals, and Europe lists delayed gastric emptying itself as an uncommon reaction ^[1][2].

What is plausible but not measured: none of the documents shows that slower emptying is the direct cause of vomiting. They report that vomiting rose with dose and clustered around dose increases, which fits the idea without proving it.

General background: MedlinePlus names glutide medicines among the treatments that can cause nausea and vomiting, alongside many other causes ^[6].

Other causes worth considering

• Stomach bugs and food poisoning, especially if others who ate the same food are ill ^[6].
• Reflux, migraine, pregnancy and motion sickness ^[6].
• Severe pain from elsewhere, such as kidney stones ^[6].
• Conditions where vomiting is an early warning sign, such as appendicitis, a blocked bowel or ulcers ^[6].
• Within the Ozempic® label itself: pancreatitis, where vomiting may come with severe stomach pain, and gallbladder disease ^[1].

What may help

The Medication Guide and Novo Nordisk’s patient page make the same practical point: drinking fluids helps lower the chance of dehydration, and vomiting that does not stop should be reported ^[1][8]. The patient page also suggests following the dose escalation schedule your prescriber sets ^[8].

MedlinePlus advises drinking small amounts of clear liquids often while you are being sick, and for dehydration suggests sipping water, sucking ice cubes or drinking fluids that contain electrolytes, while avoiding salt tablets ^[6][7]. Medicines to stop vomiting are a question for your prescriber or pharmacist, who will know your other prescriptions.

What to note for your provider

Write down how many times you vomited and over how many hours, whether you could keep fluids down, when you last passed urine and what colour it was, and whether there was pain, fever or blood. Add the date of your last injection and of any recent dose increase.

Water reminders and daily notes for fluids and meals sit in the same app as your dose log, which helps when someone asks how much you have actually been drinking.

Ozempic® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.